<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657123</url>
  </required_header>
  <id_info>
    <org_study_id>33088</org_study_id>
    <nct_id>NCT01657123</nct_id>
  </id_info>
  <brief_title>Exercise Capacity and Recovery in Addison's Disease</brief_title>
  <official_title>Effect of Hydrocortisone Stress Dose on Exercise Capacity and Post-exercise Recovery in Patients With Addison's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exposure to stress alters the activity of the adrenomedullary, adrenocortical and sympathetic&#xD;
      nervous system, depending on the type and intensity of the stressor. Physical exercise&#xD;
      represents a stress condition influencing many systems in the body. Given a workload of at&#xD;
      least 70-85% of Vo2max, exercise is a potent stimulus of the hypothalamic-pituitary-adrenal&#xD;
      (HPA)-axis. The increased endogenous cortisol secretion results in important metabolic and&#xD;
      cardiovascular effects to maintain cellular and organ homeostasis. Patients with Addison's&#xD;
      disease are not able to meet the increased demand of adrenal steroids in case of physical&#xD;
      exercise, which may result in an impaired exercise capacity and a prolonged post-exercise&#xD;
      recovery. We hypothesize that a hydrocortisone stress dose increases exercise capacity and&#xD;
      improves post-exercise recovery in patients with Addison's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exercise capacity</measure>
    <time_frame>140 minutes</time_frame>
    <description>power in Watt and duration in minutes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Addison's Disease</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrocortisone stress dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ergometry</intervention_name>
    <description>ergometry measurements</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ergometry</intervention_name>
    <description>Ergometry measurements</description>
    <arm_group_label>hydrocortisone stress dosage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Addison's disease&#xD;
&#xD;
          -  18-50 years&#xD;
&#xD;
          -  stable glucocortiocid replacement therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of intercurrent (acute) infectious disease&#xD;
&#xD;
          -  Mental impairment (major depressive, anxiety, panic, adjustment, bipolar, psychotic,&#xD;
             posttraumatic or borderline personality disorder)&#xD;
&#xD;
          -  Presence of the following chronic diseases: diabetes mellitus, chronic obstructive&#xD;
             pulmonary disease, renal failure, chronic anaemia, malignancy, rheumatoid arthritis&#xD;
&#xD;
          -  Presence of the following cardiovascular conditions: unstable angina pectoris, history&#xD;
             of myocardial infarction, uncontrolled cardiac arrhythmias causing symptoms or&#xD;
             hemodynamic compromise, symptomatic (severe) aortic stenosis, uncontrolled symptomatic&#xD;
             heart failure, acute myocarditis or pericarditis, left main coronary stenosis,&#xD;
             moderate stenotic valvular heart disease, tachyarrhythmias or bradyarrhythmias,&#xD;
             hypertrophic cardiomyopathy and other forms of outflow tract obstruction, high-degree&#xD;
             atrioventricular block&#xD;
&#xD;
          -  History of pulmonary embolus or pulmonary infarction&#xD;
&#xD;
          -  Known aortic aneurysm&#xD;
&#xD;
          -  Severe hypertension (&gt;170/100 mm Hg)&#xD;
&#xD;
          -  Medication that affects cardiovascular function (beta-blocker, calcium antagonist,&#xD;
             ACE-inhibitors, aldosterone-antagonists)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisanne Smans, drs</last_name>
    <phone>0031616796646</phone>
    <email>l.c.c.j.smans@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre Zelissen, dr</last_name>
    <phone>0031887550686</phone>
    <email>p.m.j.zelissen@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisanne Smans, drs</last_name>
      <phone>0031616796646</phone>
      <email>l.c.c.j.smans@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pierre Zelissen, dr</last_name>
      <phone>0031887550686</phone>
      <email>p.m.j.zelissen@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2012</study_first_posted>
  <last_update_submitted>August 2, 2012</last_update_submitted>
  <last_update_submitted_qc>August 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Smans</investigator_full_name>
    <investigator_title>drs</investigator_title>
  </responsible_party>
  <keyword>exercise capacity</keyword>
  <keyword>Addison's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Addison Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

